NEW YORK, Feb. 25 (UPI) -- Pfizer Inc. in New York said the trial of its pneumonia immunization in adults age 65 and older against bacterial pneumonia achieved its goals. The Community-Acquired Pneumonia Immunization Trial in Adults, the ...
US-based pharmaceutical manufacturer and marketer Forest Laboratories (FRX) has received qualified infectious disease product (QIDP) designation for its ceftazidime/avibactam drug from the US Food and Drug Administration (FDA). Currently ...
Tags: drug, Forest Laboratories
The US Food and Drug Administration (FDA) has cleared Theravance's Vibativ (telavancin) for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP). With a dual mechanism of action, the bactericidal, ...
Tags: Health&Medicine, FDA, US
Cubist Pharmaceuticals has received the US Food and Drug Administration (FDA) fast track status for its late-stage antibiotic candidate ceftolozane/tazobactam in the previously granted Qualified Infectious Disease Product (QIDP) ...
Tags: Cubist, Fast Track Status